Difference between revisions of "Durvalumab (Imfinzi)"
(FDA approval) |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
| + | *[[Non-small cell lung cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 18: | Line 19: | ||
==Also known as== | ==Also known as== | ||
| − | MEDI4736 | + | *'''Code name:''' MEDI4736 |
| + | *'''Brand name:''' Imfinzi | ||
==References== | ==References== | ||
| Line 24: | Line 26: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Immunotherapy]] | ||
| − | |||
[[Category:T-cell activators]] | [[Category:T-cell activators]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-PD-L1 antibodies]] | [[Category:Anti-PD-L1 antibodies]] | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
| − | + | [[Category:Non-small cell lung cancer medications]] | |
[[Category:Drugs FDA approved in 2017]] | [[Category:Drugs FDA approved in 2017]] | ||
Revision as of 21:32, 16 November 2017
General information
Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses. Durvalumab binds to PD-1 and CD80 (B7.1) receptors on T-cells and antigen presenting cells and prevents PD-L1's inhibitory effects on the immune system. As a result, durvalumab stimulates immune responses, including anti-tumor immune effects. Durvalumab is being investigated for potential use as monotherapy or in combination with tremelimumab (ticilimumab) in non-small cell lung cancer, head and neck cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatocellular carcinoma, and blood cancers.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 5/1/2017: Granted FDA accelerated approval "for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy."
Also known as
- Code name: MEDI4736
- Brand name: Imfinzi